liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
Oslo University Hospital, Norway .
University of Lund Hospital, Sweden .
University of Southern Denmark, Denmark .
University of Copenhagen Hospital, Denmark .
Show others and affiliations
2014 (English)In: BMC Cancer, ISSN 1471-2407, Vol. 14, no 68Article in journal (Refereed) Published
Abstract [en]

Background: We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. Methods: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Results: Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95% CI: 2.1-3-1). In the ER positive patients the median overall survival (OS) time was 13.3 months (95% CI: 7.7-18.9), in the ER negative patients the corresponding numbers were 6.1 months (95% CI: 4.1-8.2). Treatment with exemestane was well tolerated. Conclusion: Treatment of estrogen positive advanced or recurrent endometrial cancer with exemestane, an aromatase inhibitor, resulted in a response rate of 10% and lack of progression after 6 months in 35% of the patients.

Place, publisher, year, edition, pages
BioMed Central , 2014. Vol. 14, no 68
Keyword [en]
Aromatase inhibitor; Exemestane; Endometrial cancer; Treatment; Phase II study
National Category
Cancer and Oncology
URN: urn:nbn:se:liu:diva-106103DOI: 10.1186/1471-2407-14-68ISI: 000332489500003OAI: diva2:714183
Available from: 2014-04-25 Created: 2014-04-24 Last updated: 2015-06-10

Open Access in DiVA

fulltext(481 kB)151 downloads
File information
File name FULLTEXT01.pdfFile size 481 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Åvall-Lundqvist, ElisabethRosenberg, Per
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Oncology
In the same journal
BMC Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 151 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 76 hits
ReferencesLink to record
Permanent link

Direct link